Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: A systematic review and meta-analysis of randomized controlled trials

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 626-638

  Prica, Anca ^a   Sholzberg, Michelle ^b   Buckstein, Rena ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Myelodysplastic syndromes; Thrombopoiesis; Thrombopoietin; Thrombopoietin receptor agonist

Indexed keywords

AZACITIDINE; DECITABINE; ELTROMBOPAG; LENALIDOMIDE; PLACEBO; ROMIPLOSTIM; FC RECEPTOR; HYBRID PROTEIN; MPL PROTEIN, HUMAN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CANCER GROWTH; CANCER MORTALITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; AGONISTS; CHEMICALLY INDUCED; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; MEDLINE; METABOLISM; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RISK FACTOR;

FEMALE; HEMORRHAGE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEDLINE; MYELODYSPLASTIC SYNDROMES; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RISK FACTORS; THROMBOPOIETIN;

EID: 84925221726     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13088     Document Type: Article

References (29)

1. Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. & Tura, S.; Italian Society of Hematology (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 1286-1306.
2. Buckstein, R., Jang, K., Chesney, A., Reis, M.D., Friedlich, J., Zhang, L. & Wells, R.A. (2007) Estimating the prevalence and a pre-test likelihood of myelodysplasia: a retrospective review of bone marrow histopathology in 322 cases of unexplained cytopenia(s) in a teaching hospital. Leukemia Research, 31, S23, Abstract C001.
3. Callum, J.L., Pinkerton, P.H., Karkouti, K., Prendergast, J.M., Robitaille, N., Tinmouth, A.T. & Webert, K.E. (2011) Bloody Easy 3: Blood Transfusions, Blood Alternatives and Transfusion Reactions: a Guide to Transfusion Medicine, 3rd edn. Ontario Regional Blood Conservation Network, Toronto.
4. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Löwenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L.; for the World Health Organization(WHO) international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
5. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
6. Doll, D.C. & List, A.F. (1989) Myelodysplastic syndromes. Western Journal of Medicine, 151, 161-167.
7. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R.; International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology, 10, 223-232.
8. Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Te Boekhorst, P., Sanz, G., Del Cañizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lübbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T. & Hellström-Lindberg, E.; MDS-004 Lenalidomide del5q Study Group. (2011) A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118, 3765-3776.
9. Giagounidis, A., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Hu, K., Woodard, P., Yang, A.S. & Kantarjian, H.M. (2014) Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer, 120, 1838-1846.
10. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
11. Greenberg, P.L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., Yang, A.S. & Franklin, J. (2013) A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia and Lymphoma, 54, 321-328.
12. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. & Schünemann, H.J.; GRADE Working Group. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336, 924-926.
13. Heddle, N.M., Cook, R.J., Webert, K.E., Sigouin, C. & Rebulla, P.; for the Biomedical Excellence for Safer Transfusion Working Party of the International Society for Blood Transfusion (2003) Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 43, 742-752.
14. Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M.A., Pierce, S., Deuson, R. & Leveque, J. (2007) The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 109, 1705-1714.
15. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P.S., Boruchov, A., Bowen, D., Hellstrom-Lindberg, E., Larson, R.A., Lyons, R.M., Muus, P., Shammo, J., Siegel, R., Hu, K., Franklin, J. & Berger, D.P. (2010a) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology, 28, 437-444.
16. Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L. & Berger, D.P. (2010b) Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 116, 3163-3170.
17. Kantarjian, H.M., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Bennett, J.M., Meibohm, A., Yang, A.S. & Giagounidis, A. (2012) Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (PTS) with low or intermediate-1 (INT-1) risk myelodysplastic syndrome (MDS): Follow-up aml and survival results of a randomized, double-blind, placebo (PBO)-controlled study. Blood, 120, 421.
18. Mittelman, M., Assouline, S., Briasoulis, E., Alonso, A., Delgado, R., O'Gorman, P., Kim, HJ, Yoon, S.-S., Zaritskey, A., Flynn, C.M., Min, Y.-H., Diez-Campelo, M., Myasnikov, A., Mannino, F., Kamel, Y.M., Messam, C., Stone, N.L. & Chan, G.W. (2012) Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-Week open-label part of an ongoing study. Blood, 120, 3822.
19. Oliva, E.N., Santini, V., Zini, G., Palumbo, G.A., Poloni, A., Cortelezzi, A., Voso, M.T., Molteni, A., Sanpaolo, G., Marino, A., Roda, F., Alati, C., Ronco, F., Di Raimondo, F., Leoni, P., Alimena, G., Finotto, S., Latagliata, R. & Nobile, F. (2012) Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQOL-MDS). Blood, 120, 923.
20. Oshima, Y., Yuji, K., Tanimoto, T., Hinomura, Y. & Tojo, A. (2013) Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Internal Medicine, 52, 2193-2201.
21. Picozzi, V.J., Swanson, G.F., Morgan, R., Hecht, F. & Greenberg, P.L. (1986) 13-cis retinoic acid treatment for myelodysplastic syndromes. Journal of Clinical Oncology, 4, 589-595.
22. Platzbecker, U., Wong, R., Verma, A., Abboud, C., Araujo, S., Chiou, T., Feigert, J., Yeh, S., Gotze, K., Gorin, N., Greenberg, P., Kambhampati, S., Kim, Y., Lee, J., Lyons, R., Ruggeri, M., Santini, V., Cheng, G., Jang, J., Chen, C., Dougherty, S., Mannino, F., Kamel, Y., Chan, G., Arning, M., Stone, N. & Giagounidis, A. (2013) Placebo-Controlled, Randomized, Phase I/II Trial Of The Thrombo-poietin Receptor Agonist Eltrombopag In Throm-bo-cy-to-penic Patients With Advanced Myelo-dys-plas-tic Syn-dromes Or Acute Myeloid Leu-kemia. Haematologica, S1., p. S1108 abstract.
23. Powell, B.L., Capizzi, R.L., Jackson, D.V., Richards, F., Muss, H.B., Lyerly, E.S., Rosenbaum, D.L., Connelly, R.A., Buss, D.H. & Bearden, J.D. (1988) Low dose Ara-C for patients with myelodysplastic syndromes. Leukemia, 2, 153-156.
24. Schiffer, C.A., Anderson, K.C., Bennett, C.L., Bernstein, S., Elting, L.S., Goldsmith, M., Goldstein, M., Hume, H., McCullough, J.J., McIntyre, R.E., Powell, B.L., Rainey, J.M., Rowley, S.D., Rebulla, P., Troner, M.B. & Wagnon, A.H.; for the American Society of Clinical Oncology (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1519-1538.
25. Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429-2440.
26. Tiu, R.V. & Sekeres, M.A. (2008) The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opinion on Biological Therapy, 8, 1021-1030.
27. Wang, E.S., Lyons, R.M., Larson, R.A., Gandhi, S., Liu, D., Matei, C., Scott, B., Hu, K. & Yang, A.S. (2012) A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology and Oncology, 5, 1-13.
28. Wu, H.H., Talpaz, M., Champlin, R.E., Pilat, S.R. & Kurzrock, R. (2003) Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer, 98, 2410-2419.
29. Zeidman, A., Sokolover, N., Fradin, Z., Cohen, A., Redlich, O. & Mittelman, M. (2004) Platelet function and its clinical significance in the myelodysplastic syndromes. Hematology Journal, 5, 234-238.